A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma
- 1 January 2008
- journal article
- research article
- Published by Informa UK Limited in Cancer Investigation
- Vol. 26 (3), 269-277
- https://doi.org/10.1080/07357900701708393
Abstract
Dose-dense temozolomide schedules deplete O6-methylguanine methyltransferase and may overcome chemoresistance. This multicenter cohort study enrolled 19 patients (15 anaplastic astrocytoma, 4 anaplastic oligoastrocytoma) who received temozolomide (100 mg/m2/day for 21 consecutive days every 28-day cycle) at first recurrence, either until disease progression or 12 cycles. Six-month progression-free survival was 56%, comparing favorably with historic controls treated with the standard 5-day temozolomide schedule. Median survival was 12.9 months (95% CI: 3.7, 22 months). Among 15 evaluable patients, 2 had a complete or partial response, and 10 had stable disease. Grade 3 and 4 lymphopenia occurred in 53% and 47% of patients, respectively.Keywords
This publication has 21 references indexed in Scilit:
- Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent GliomaJournal of Clinical Oncology, 2007
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)British Journal of Cancer, 2006
- Is protracted low-dose temozolomide feasible in glioma patients?Neurology, 2006
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary GliomasClinical Cancer Research, 2004
- Temozolomide in the treatment of recurrent malignant gliomaCancer, 2004
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBritish Journal of Cancer, 2003
- Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating AgentsNew England Journal of Medicine, 2000
- Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarrazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final reportInternational Journal of Radiation Oncology*Biology*Physics, 1990